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ABSTRACT
Penicillin class antibiotics have demonstrated varying degrees of in vivo and in vitro success when
tested against Chlamydia trachomatis. The activity of ampicillin-sulbactam, an agent commonly
utilized in the treatment of pelvic infections, was tested to ascertain if any antichlamydial activity is
present. Up to six endocervical isolates of C. trachomatis were tested against each of five antibiotics
including doxycycline, erythromycin, clindamycin, ampicillin/sulbactam, and sulbactam alone. Mc-
Coy cell monolayers were inoculated with high inclusion counts of 10,000-30,000 inclusion-forming
units (IFU) per coverslip, and exposed to each antibiotic. Up to nine subsequent antibiotic free
culture passes were performed to assess the viability of abnormal inclusions. Doxycycline, erythro-
mycin, and clindamycin achieved 100% eradication of inclusions at concentrations of 4.0, 2.0, and
1.0 g/mL. Exposure to ampicillin/sulbactam resulted in a greater than 99% reduction in the inclu-
sion count at 32.0 g/mL, while sulbactam by itself demonstrated considerably less activity. Abnor-
mal inclusions were noted only in the ampicillin/sulbactam exposed cells, and these, plus all inclu-
sions remaining following sublethal exposure to the other antibiotics, resulted in regrowth to control
levels in subsequent passes. Doxycycline and erythromycin demonstrated excellent activity. Clin-
damycin and ampicillin/sulbactam also significantly reduced inclusion formation, and therefore may
provide adequate C. trachomatis coverage in patients receiving these antibiotics for pelvic infections.
(C) 1993 Wiley-Liss, Inc.
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hlamydia trachomatis is one of the most preva-
lent sexually transmitted organisms of the fe-
male genital tract. Infection may result in serious
sequelae such as infertility, ectopic pregnancy, and
pelvic inflammatory disease. Treatment regimens
usually consist oftetracycline or erythromycin; how-
ever, sulfa drugs and clindamycin have demon-
strated good activity, z’3
Penicillin-based antibiotics have demonstrated
efficacy in some in vitro studies, 4’5 and in fact have
recently been recommended as an alternative ther-
apy to erythromycin in the treatment of chlamydial
infection in pregnancy.
6 However, due to the elon-
gated life cycle of C. trachomatis, single dose ther-
apy with penicillin G, tetracycline, or erythromy-
cin does not cure cases of urethritis caused by C.
trachomatis.
6
Penicillins have also been noted to produce ab-
normal inclusions, which may revert to normal at a
later time.
7 This observation may have possibly
discouraged the study of newer broad spectrum
penicillins for treatment of C. trachomat# infec-
tions despite early, although limited, clinical suc-
cess. Penicillins have been reported to eradicate C.
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trachomatis in eight of ten women treated with a
21-day course of ampicillin for cervical and/or ure-
thral infection.
8 Bowie et al. reported the microbi-
ological cure in six of six men with urethritis when
treated with a 10-day regimen of amoxicillin.
9
Martin et al. reported the microbiological cure of
C. trachomatis infection in seven patients treated
with ticarcillin/clavulanic acid, whereas three pa-
tients treated with cephalosporins remained culture
positive after treatment.
5 These results correlated
well with their in vitro susceptibility results of 19
isolates of C. trachomatis against broad spectrum
semi-synthetic penicillin and cephalosporins.
Ticarcillin, mezlocillin, and piperacillin exhibited
good in vitro susceptibility results in 19 isolates of
C. trachomatis, while cefoxitin, cefotaxime, and
cefamandole exhibited poor in vitro activity.
Also, despite excellent in vitro activity, treat-
ment failures with the current drugs of choice,
tetracycline and erythromycin, have also been re-
ported.
6-1 Similarly, in vitro resistance of eryth-
romycin has been reported, but is rare.
Several investigators have attempted to predict
clinical efficacy of antibiotic regimens by perform-
ing in vitro susceptibility testing. However, be-
cause of the variety of in vitro susceptibility testing
techniques that have been utilized, clinical correla-
2,4,7,8,12--17 tions do not always agree.
The present investigation provides additional
information concerning the susceptibility pattern
for various antibiotics, including ampicillin/
sulbactam, which may be clinically useful in the
treatment of chlamydial infections.
SUBJECTS AND METHODS
Source of Isolates
Endocervical specimens were collected from two
patient populations: 1) nonpregnant adolescents at-
tending a teen health clinic; and 2) postpartum
patients who were evaluated for endometritis.
Processing of Specimens
A Dacron swab was inserted in the endocervix after
the portion of the cervix had been cleansed with a
cotton-tipped applicator. The swab was rotated sev-
eral times to collect cellular material and was then
placed in Chlamydia transport medium. The trans-
port tube was refrigerated (2-8C) and kept on ice
until delivery to the laboratory (within 24 hours).
Upon receipt in the laboratory, the transport
tubes were vortexed for 30 seconds to remove cellu-
lar material from the fiber matrix. Excess moisture
was removed from the swab by pressing it against
the side of the tube as it was withdrawn, and the
swab was then discarded. The tubes were centri-
fuged at 200g for 5 minutes to remove debris. The
supernatant (0.3 mL) was used to inoculate McCoy
cell monolayers grown on coverslips contained in
1-dram vials after the overlay medium had been
removed. All transport tubes were then frozen at
-70C. The inoculated vials were centrifuged for
hour at 3,000g at 35C for hour. Fresh isola-
tion medium was added, and the vials were incu-
bated for an additional 48-72 hours before stain-
ing. The Chlamydia transport media, McCoy cell
monolayers, and isolation medium were obtained
from Bartels Immunodiagnostics (Bellevue, WA).
The McCoy cell monolayers were stained with
Jones’ iodine or with Chlamydia-specific fluores-
cent antibody (FA) reagent (Ortho Diagnostic,
Raritan, NJ).
Susceptibility Testing
Stock solutions (100 x highest concentration tested)
were prepared in minimal essential medium
(MEM). Aliquots were frozen at -70C for no
longer than 30 days before use. The concentrations
(Ixg/mL) of the antibiotics tested were as follows:
clindamycin 0.25, 0.50, and 1.0; doxycycline 4.0,
8.0, and 16.0; and sulbactam 3, 6, and 12. Slightly
higher concentrations were utilized due to the high
Chlamydia inoculum used. Ampicillin/sulbactam
(Roerig, Groton, CT), were tested at a 2:1 ratio of
ampicillin (6, 12, and 24 Ixg/mL) to sulbactam.
The earlier penicillins have been tested extensively
and therefore ampicillin was not included in this
investigation.2’4’5
Frozen transport media was thawed and used to
inoculate five vials of McCoy cells. After 48-72
hours, McCoy cell vials were prepared for passage
by first centrifuging at 3,000g for 30 minutes to
reassociate elementary bodies with the monolayer.
The overlay medium was then decanted and re-
placed with 0.4 mL 2 sucrose phosphate medium
(2SP). The McCoy cell vials were frozen twice at
-70C, thawed, and sonicated in an ultrasonic bath
for 2 minutes. The sonicated suspensions were
passed through a sterile 1.2-1xm syringe tip filter to
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TABLE I. Activity of antibiotics vs. Chlamydia trachomatis
No. of
Antibiotic isolates Concentration (lg/mL)
0.25 0.5 1.0
Sulbactam 5
Ampicillin/sulbactam 5
Clindamycin 6 99 99 100
Doxycycline S
Erythromycin 5
2.0 4.0 8.0 16.0 32.0
0 64 68
95 95 99
I00 I00 I00
I00 I00 I00
not tested.
bConcentrations utilized for sulbactam: 3, 6, and 12 Ig/mL.
CPercentage of inclusions inhibited at each concentration of antibiotic.
remove cell debris. A 0.1 mL portion of the sus-
pension was used to inoculate new vials. At least
three passes were performed using MEM overlay
media with antibiotics. An additional three passes
were performed using MEM overlay media with-
out antibiotics and with 5% heat inactivated fetal
calf serum. McCoy cells were also maintained in
MEM without antibiotics for 3 days prior to inoc-
ulation. An inoculum containing 10,000-30,000
IFUs per coverslip was obtained with this method.
A 0.1-mL portion of the final inoculum was
added to each of four McCoy cell monolayers at
each antibiotic concentration and centrifuged for
hour at 3,000g, 30C. The monolayers were incu-
bated for hour at 35C. Feeding MEM contain-
ing the desired concentrations of antibiotics tested
was then added to the monolayer. The monolayers
were incubated for 48 hours. Two of the monolay-
ers were stained, and two were used for a passage
into four new vials. Between the first and second
passes, monolayers were washed with antibiotic-
free MEM to remove residual antibiotic. For pas-
sage, 2 mL of 2SP media were added per vial. The
cell layer was then disrupted with a Pasteur pipette,
frozen at -70C, thawed, refrozen, and sonicated.
Additional passes were performed for each isolate
until regrowth of initial inoculum size or no
growth occurred up to a total of ten passes. This
procedure produced an inoculum containing ele-
mentary bodies without cell debris. Antibiotic-free
medium was added to triplicate inoculated McCoy
cells as control. Monolayers were stained with a
fluorescent antibody reagent, (Ortho Diagnostics).
Layers were then examined microscopically, and
the number of normal inclusions, if any, was deter-
mined.
RESULTS
Five clinically recovered isolates of C. trachomatis
were tested against sulbactam, ampicillin/
sulbactam, doxycycline, and erythromycin. Six iso-
lates were utilized in the clindamycin group. Good
activity against C. trachomatis was demonstrated by
all antibiotics at normally achievable serum levels
with the exception of sulbactam. Percent inhibi-
tions at various antibiotic concentrations are listed
in Table I. Minimal concentrations to inhibit 90%
growth (MIC90) were <0.25 Ig/mL for clin-
damycin, <2.0 Ig/mL for erythromycin, <4.0
Ig/mL for doxycycline, <8.0 Ig/mL for
ampicillin/sulbactam, and >64 Ig/mL for sulbac-
tam alone.
Normal inclusions were noted following antibi-
otic exposure to sulbactam, clindamycin, doxycy-
cline, and erythromycin as well as the control
groups, and were regular in shape and stained uni-
formly in brilliant green (Fig. 1). Abnormal inclu-
sions were smaller, misshaped, appeared hollow,
and stained faintly (Fig. 2), and were noted only
following exposure to ampicillin/sulbactam.
Maximum inhibition occurred after the antibi-
otic-treated pass (first pass), and regrowth of inclu-
sions to pretreated levels occurred with ampicillin/
sulbactam, sulbactam alone, and clindamycin.
Regrowth to control levels occurred after a mean of
six passes. No regrowth of C. trachomatis occurred
with doxycycline or erythromycin at any for the ten
passes performed following exposure to the initial
concentrations of antibiotic.
DISCUSSION
Several antibiotics have demonstrated varying lev-
els of" activity against C. trachomatis. However, the
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Fig. I. Normal inclusion. Fluorescent antibody stain, 400.
Fig. 2. Abnormal inclusion. Fluorescent antibody stain, 400.
tetracyclines and erythromycins, as well as their
derivatives, have consistently demonstrated excel-
lent in vitro and in vivo activity. Contraindications
in pregnant patients, compliance, or tolerance
problems have prompted the investigation of other
antimicrobial agents. Penicillin class antibiotics are
believed to be generally safe in pregnancy and are
often better tolerated than erythromycin. Several
investigations have demonstrated excellent in vitro
and in vivo activity, as mentioned earlier. How-
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ever, susceptibility testing of C. trachomatis to pen-
icillin is complicated by the production of abnor-
mal inclusion bodies and the difficulty oflong-term
clinical follow-up necessary for correlation of in
vivo and in vitro findings.
The abnormal inclusions are readily detectable
by FA staining (Figs. 1, 2), and this perhaps
should be the method of choice for detecting inclu-
sions during C. trachomatis susceptibility testing
with the penicillins. However, the use ofFA stain-
ing and the detection of abnormal inclusions com-
promises some investigators’ definition of MIC
and MBCs. Heretofore, the MIC values repre-
sented the concentration of antibiotic that inhibited
the development of inclusions in McCoy cells. The
MBC value represented the concentration of anti-
biotics that prevented regrowth of inclusions in
antibiotic-free McCoy cells. Other investigators
have utilized a variety of means to compare the
activity of penicillin and other antibiotics. Bowie
utilized MIC, MBC, and >99% decrease in inclu-
sion formation.
4 Martin et al. utilized percentage
inhibition at various antibiotic concentrations.
5
However, until the viability and importance of
abnormal inclusions are better understood, great
variability in the reporting of anti-chlamydial ac-
tivity will probably continue.
In this investigation, ampicillin/sulbactam, clin-
damycin, doxycycline, and erythromycin demon-
strated good in vitro activity at concentrations
readily achievable in human serum. Only doxycy-
cline and erythromycin eliminated all inclusions
consistently, with no regrowth of inclusions, de-
spite ten passes. While the penicillins failed to
eradicate inclusion formation entirely, their activ-
ity was comparable to clindamycin when examined
at the extremely high inoculum utilized in these
tests. Therefore, in patients being treated for pelvic
or other infections with ampicillin/sulbactam or
clindamycin, additional coverage of chlamydial in-
fections with erythromycin and doxycycline may
not be necessary. Perhaps reculturing of the patient
can demonstrate eradication of the chlamydia, and
save the patient the additional expense and compli-
cations of these antibiotics.
The regrowth of the clindamycin-treated cells
can be explained by the incomplete eradication of
C. trachomatis at lower doses of clindamycin with
subsequent regrowth of few, but viable, remaining
inclusions. However, one sample demonstrated re-
growth after four passes in which no inclusions
were noted after antibiotic exposure, perhaps signi-
fying elementary bodies in the absence of formed
inclusions. Thus, the cause of inclusion regrowth
with ampicillin/sulbactam may not necessarily be
due to the abnormal inclusions, but to a similar
regrowth of low numbers of inclusions or individ-
ual elementary bodies. Regardless of the etiology of
regrowth of inclusions after subsequent antibiotic-
free passes in vitro, it is difficult to utilize these
results to predict in vivo efficacy.
Sulbactam, by itself, demonstrated poor activity
against C. trachomatis, similar to previously pub-
lished reports with other [3-1actamase inhibitors.
4
However, the combination ampicillin/sulbactam
demonstrated good activity, with a reduction in
inclusion counts similar to clindamycin at achiev-
able serum levels. Clindamycin has been recom-
mended (or the treatment of C. trachomatis by the
Centers for Disease Control,
18 although it is not
their primary agent due to doxycycline’s excellent
activity. Penicillin’s activity in clinical trials is en-
couraging, if limited. In vivo, both antibiotics’
activities may be augmented by host defenses that
combine with the antibiotic’s activity to eradicate
the infection. However, because of the regrowth of
inclusions after initial inhibition, adequate clinical
trials need to be completed. Emphasis on long-term
follow-up is critical in order to assess the possible
regrowth of previously inhibited, but not eradi-
cated inclusions.
The high inoculum utilized in this investigation
is artificially achieved, and probably not similar to
actual clinical infections. However, it confirms the
excellent activity of the tetracyclines and erythro-
mycins, while still highlighting good activity for
those antibiotics that may be bacteriostatic, if not
bacteriocidal.
Thus, in summary, in vitro susceptibility testing
of C. trachomatis confirmed the excellent activity of
doxycycline and erythromycin. Clindamycin and
ampicillin/sulbactam demonstrated good activity,
with greater than 99% reduction of inclusion
counts at achievable serum concentrations. Sulbac-
tam demonstrated limited activity, consistent with
other [3-1actamase inhibitors. While clindamycin
and ampicillin/sulbactam cannot at this time be rec-
ommended as the primary treatment for chlamydial
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infections, those patients receiving these antibiotics
for other indications, in which a chlamydial culture
is reported positive, may not necessarily need addi-
tional, automatic treatment with doxycycline or
erythromycin. However, documentation of eradi-
cation of Chlamydia by repeat tissue culture is rec-
ommended.
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